Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339025 · ClinicalTrials.gov registry record
DoD-NCI TRICARE Feasibility Study
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 93
- Enrollment target
NCT02339025: Completed study, sponsored by National Cancer Institute (NCI).
NCT02339025 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02339025 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 93 participants
- Enrollment target
Study Summary
Background: \- Researchers at the National Cancer Institute and the Department of Defense are trying to learn more about what causes cancer, heart disease, and other health problems. To do this, they gather data on risk factors and biological markers. They get these data from large groups of people in long-running studies. As these groups of people age, researchers must form new groups. TRICARE is a health insurance program for uniformed service members and their families. It is a major part of the Military Health System. Researchers hope to form a new study group from TRICARE members. This study will test if TRICARE members will take part in a research study. Objectives: \- To test if TRICARE members will take part in a research study. Eligibility: \- TRICARE members aged 35 74 with military primary care providers at Walter Reed National Military Medical Center. They must not have a prior diagnosis of cancer other than non-melanoma skin cancer. Design: * Participants will fill out a survey. It will ask about their risk factors for cancer and other chronic diseases. Their medical records will be reviewed. They will give a blood sample. * If a larger study is formed, then participants data will be used in the larger study. They may be asked to give more samples.
Primary Outcome
Participant rates
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-08-18 |
| Est. Completion | 2019-09-23 |
What the finished NCT02339025 record still lists
NCT02339025 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02339025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02339025 about?
NCT02339025 is a clinical study titled "DoD-NCI TRICARE Feasibility Study". Background: \- Researchers at the National Cancer Institute and the Department of Defense are trying to learn more about what causes cancer, heart disease, and other health problems. To do this, they gather data on risk factors and biological markers. They get these data from large groups of people...
What is the current status of trial NCT02339025?
This trial is currently completed. The enrollment target is 93 participants. The study started on 2018-08-18. Estimated completion is 2019-09-23.
Who is sponsoring clinical trial NCT02339025?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI